

Ethnopharmacology-Guided Drug Discovery from Natural Products: Therapeutic Potential and Toxicological Challenges

Ms. Samiksha Bangar¹, Dr. Priti Patel¹.

¹Department of Pharmaceutical Quality Assurance, Dr. L. H. Hiranandani College of Pharmacy UNR-03, Thane, Maharashtra, India.

Corresponding author: [priti.patel@dlhhcop.org]

Doi: <https://doi.org/10.5281/zenodo.22302373>

Received: 08th July 2026

Accepted: 18th July 2026

Abstract:

The increasing burden of chronic and infectious diseases has intensified the search for novel therapeutic agents, with natural products remaining a major source of drug leads. Ethnopharmacology, the scientific study of traditional medicinal knowledge, provides a targeted approach to natural product-based drug discovery. This review outlines the ethnopharmacology-guided drug discovery pipeline, highlights major plant-derived therapeutics, discusses toxicological challenges, and examines the role of emerging technologies in advancing the field. Landmark drugs such as paclitaxel, vincristine, artemisinin, galantamine, digoxin and berberine demonstrate the clinical value of ethnopharmacological knowledge. However, safety concerns including hepatotoxicity, aristolochic acid nephropathy, herb-drug interactions and standardization issues require careful evaluation. Modern tools such as artificial intelligence, network pharmacology, metabolomics, nanotechnology and synthetic biology are accelerating natural product research. Combined with ethical frameworks such as the Nagoya Protocol and the WHO Traditional Medicine Strategy, these advances support the responsible integration of traditional knowledge into modern drug development. Ethnopharmacology-guided discovery remains a promising strategy for future pharmaceutical innovation.

Keywords: Ethnopharmacology, Natural products, Drug development, Phytochemistry, Toxicology, Bioactive chemicals, Traditional medicine, Herb-drug interactions.

1. Introduction:

The Global Burden of Disease Study 2019 (GBD 2019) calculated incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 369 illnesses and injuries across 204 countries and territories. Age standardized measurements have shown that global health has been progressively improving over the last 30 years. But although individuals are significantly less likely to die early of contagious diseases than they were 30 years ago, the new problem is dealing with chronic illnesses and everyday limitations that come with old age ^[1].

For thousands of years medicine and natural goods have extensive and unseparable history. All the drugs that revolutionized modern medicine were derived from nature: morphine from the opium poppy *Papaver somniferum*, aspirin from the bark of the willow tree (*Salix species*), penicillin from the fungus *Penicillium notatum* and artemisinin from *Artemisia annua*, a plant used in Chinese traditional medicine for over 2000 years ^[3]. The fact that so many life-saving pharmaceuticals have natural roots is not just a coincidence, but a regular and dependable trend — that millennia of human observation of nature pre-validated numerous therapeutic leads long before contemporary science verified them.

Natural products are still a valuable source of new therapeutic agents for the ever-changing panorama of illness. Newman and Cragg examined 39 years of data on licensed medications and concluded that most pharmaceuticals came from nature. When anticancer medications connected to natural products were studied, 64.9% of anticancer drugs were originated from nature from 1981 to 2019. For many infectious disorders natural products are still prevailing and most antibiotics are of natural origin. Natural compounds and their derivatives are still commonly identified and authorized overall for most ailments although, completely manufactured medications contribute relatively little compared. So nature still wins ^[2].

Ethnopharmacology is the scientific study of traditional medicine systems that links culture to contemporary science to analyze how indigenous people employ plants, animals and minerals to heal. Traditional medicine systems like Ayurveda, Traditional Chinese Medicine (TCM), African ethnomedicine and Unani have recorded hundreds of medicinal plants over ages which is a remarkable storehouse of untapped therapeutic potential ^{[4][5]}. The ethnopharmacology-guided drug discovery strategy is substantially more successful than random screening approaches since the usage of plants by traditional groups over centuries already gives early evidence of biological activity and appropriate safety. This targeted approach has already produced landmark drugs. Artemisinin from *Artemisia annua* was used in Traditional Chinese Medicine for centuries before scientists worked out its antimalarial mechanism, and galantamine from the Caucasian snowdrop plant used in Eastern European folk medicine is now a standard treatment for Alzheimer's disease. Despite these advances however, there remains a large gap between what traditional people know and what has been officially verified by contemporary science ^[6].

However, the translation of ethnopharmacological knowledge into clinically approved treatments with regard to toxicological safety, standardization and regulatory frameworks still remains a difficulty. In this review, we systematically examine the ethnopharmacology-guided drug discovery pipeline, evaluate the therapeutic potential of major natural product derived compounds in various disease categories, discuss existing toxicological challenges, and highlight advances in modern technologies that are accelerating and integrating this field within the contemporary pharmaceutical and biotech sciences.

2. Ethnopharmacology as a Drug Discovery Approach:

Traditional medical systems including Ayurveda, Traditional Chinese Medicine, African ethnomedicine and Unani medicine have served as important sources of medicinal knowledge and continue to provide valuable leads for modern drug discovery ^[4].

This information has been systematically recorded in ethnobotanical surveys where researchers visit and directly engage with traditional healers, community elders and local practitioners to chronicle the usage of medicinal plants, how they are prepared and what ailments they cure. This procedure provides the foundation of reverse pharmacology a drug development paradigm that starts with evidence of traditional usage, advances via clinical observation and ultimately to laboratory validation and mechanistic research, reversing the standard bench-to-bedside pipeline.

However, the commercial use of biodiversity for medicine research (bioprospecting) poses serious ethical problems of exploitation of indigenous populations and their expertise. The Nagoya Protocol, established within the framework of the Convention on Biological Diversity, establishes binding access and benefit sharing (ABS) frameworks to ensure communities whose knowledge is utilized are fairly recognized and rewarded ^[7]. For systematic research, many curated databases are built, such as NAPRALERT, among the oldest natural products databases, ETHNOBOTDB and TM-MC that compile traditional medicine claims and phytochemical data for researchers worldwide ^{[8][9]}.

3. Chemical Classes and Sources of Natural Products:

Natural products include a wide range of chemical classes with different structural properties and pharmacological significance. Alkaloids are nitrogenous chemicals with strong biological activity. Morphine and vincristine are typical examples. Terpenoids are generated from isoprene units and are the biggest class of natural chemicals that have a broad range of medicinal qualities such as artemisinin and taxol. Flavonoids and polyphenols are plant secondary metabolites that are abundant in regularly eaten fruits, vegetables and medicinal plants and their antioxidant, anti-inflammatory and anticancer effects are well known. Glycosides, such as the heart glycoside digoxin, are made of a sugar moiety connected to a bioactive aglycone, and saponins have significant immunomodulatory and cholesterol-lowering effects ^[10].

Plants remain the primary source of bioactive natural compounds, while marine organisms and microorganisms have also yielded important therapeutic agents including anticancer drugs and antibiotics.^[11] Natural products possess structural diversity and biological relevance that make them valuable scaffolds for drug development.

4. Drug Discovery Pipeline for Natural Products:

Drug Discovery Pipeline for Natural Products: Ethnopharmacological leads are developed through bioassay-guided fractionation, where extracts are separated and tested until active compounds are identified. Extraction and isolation commonly employ chromatographic techniques including HPLC and TLC^[12].

Nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry were used to determine the molecular structures of the isolated compounds. Where appropriate, X-ray crystallography was used to confirm the exact molecular structures of the lead chemical. HTS systems enable the parallel testing of vast libraries of extracts against disease targets, greatly increasing the chances of early discovery.

Lead compounds are optimised to optimize potency, selectivity and pharmacokinetic characteristics. Subsequently, compounds are put through rigorous ADMET profiling to measure absorption, distribution, metabolism, excretion and toxicity, to determine clinical viability. Compounds with promising profiles are next subjected to semisynthesis, where the natural scaffold is chemically changed to improve effectiveness, or complete synthesis, where the compound may be produced on an industrial scale without the need of natural sources as shown in the total synthesis of artemisinin derivatives^[13].

5. Therapeutic Applications

5.1. Anti-Cancer Agents: Natural products have made transformational contributions to cancer. Taxol from *Taxus brevifolia* stabilizes microtubules and stops proliferation of cancer cells; it is a first-line therapy for breast, ovarian and lung malignancies. Vincristine and vinblastine from *Catharanthus roseus* bind to tubulin and cause mitotic arrest, and are employed in the treatment of leukaemia and lymphoma. Camptothecin and its semi-synthetic derivatives irinotecan and topotecan, isolated from *Camptotheca acuminata*, block topoisomerase I, an enzyme necessary for DNA replication in rapidly proliferating cancer cells^[14].

5.2 Communicable Diseases: Artemisinin, derived from *Artemisia annua* and originally used in Traditional Chinese Medicine, is a highly effective antimalarial drug. Quinine from Cinchona bark remains important in malaria treatment, while berberine exhibits broad-spectrum antimicrobial activity against bacteria, fungi and protozoa^[15].

5.3 Cardiac Disorders: The cardiac glycoside digoxin, derived from *Digitalis lanata*, inhibits the sodium-potassium ATPase pump, increasing cardiac contractility, and is still used clinically for the treatment of heart failure and atrial fibrillation^[16]. Reserpine is one of the earliest antihypertensives that was extracted from the plant *Rauwolfia serpentina*, which has been used in Ayurvedic medicine for many centuries. Reserpine works by depleting the catecholamine reserves in the adrenergic neurons^[17].

5.4 Disorders of the nervous system and CNS: Galantamine, isolated from *Galanthus species*, is an acetylcholinesterase inhibitor approved for Alzheimer's disease treatment. Physostigmine, obtained from *Physostigma venenosum*, is used in glaucoma and anticholinergic toxicity management^[18].

5.5 Immunomodulatory and anti-inflammatory: Boswellic acids, produced from *Boswellia serrata* resin used in ayurvedic medicine, are selective inhibitors of 5-lipoxygenase (5-LOX), and they reduce leukotriene formation; they have shown therapeutic benefit in inflammatory disorders such as osteoarthritis and asthma.^[19] Withaferin A of *Withania somnifera* (Ashwagandha) is a strong immunomodulator, anti-inflammatory, and anticancer agent: the role of the NF- κ B pathway.^[20]

5.6 Diabetes: Berberine also has remarkable antidiabetic efficacy, via activating AMP-activated protein kinase (AMPK), with increases in insulin sensitivity and decreases in hepatic glucose output, with clinical results similar

to metformin in certain investigations. Gymnemic acid, derived from *Gymnema sylvestre*, a plant used in Ayurvedic therapy for centuries, decreases intestinal glucose absorption and increases the regeneration of pancreatic beta cells. It is a potential adjuvant in the treatment of type 2 diabetes ^[21].

Table 1. Some ethnopharmacology medicines and their medicinal uses

Plant / Source	Active Compound	Therapeutic Use	References
<i>Taxus brevifolia</i>	Paclitaxel (Taxol)	Anticancer	[14]
<i>Catharanthus roseus</i>	Vincristine, Vinblastine	Anticancer (Leukaemia, Lymphoma)	[14]
<i>Camptotheca acuminata</i>	Camptothecin	Anticancer	[14]
<i>Artemisia annua</i>	Artemisinin	Antimalarial	[15]
Cinchona bark	Quinine	Antimalarial	[15]
<i>Digitalis lanata</i>	Digoxin	Heart failure, Atrial fibrillation	[16]
<i>Rauwolfia serpentina</i>	Reserpine	Antihypertensive	[17]
<i>Galanthus species</i>	Galantamine	Alzheimer's disease	[18]
<i>Physostigma venenosum</i>	Physostigmine	Glaucoma, Anticholinergic toxicity	[18]
<i>Boswellia serrata</i>	Boswellic acids	Anti-inflammatory	[19]
<i>Withania somnifera</i>	Withaferin A	Immunomodulatory, Anti-inflammatory, Anticancer	[20]
Berberine-containing medicinal plants	Berberine	Antimicrobial, Antidiabetic	[15], [21]
<i>Gymnema sylvestre</i>	Gymnemic acid	Type 2 diabetes	[21]

6. Toxicological Problems:

However, natural compounds pose considerable toxicological problems which need to be properly addressed before clinical translation. One of the most well-documented concerns is hepatotoxicity; pyrrolizidine alkaloids in comfrey (*Symphytum officinale*) and *Senecio species* cause hepatic veno-occlusive disease via formation of toxic pyrrole metabolites, whereas kava (*Piper methysticum*), a popular anxiolytic, has been linked with severe idiosyncratic liver injury leading to regulatory restrictions in multiple countries.^{[22][23]} Perhaps the most serious reported case of herbal toxicity is aristolochic acid nephropathy, previously known as Chinese-herb nephropathy, caused by *Aristolochia species* used in traditional Chinese and Ayurvedic medicine. Aristolochic acid causes irreversible renal fibrosis and urothelial carcinoma and its discovery is a landmark warning for the field of nephrotoxicity ^[24]. In addition, certain alkaloids like safrole and several pyrrolizidines have genotoxic and carcinogenic potential, posing long-term safety concerns even at sub-toxic levels. Herb-drug interactions are a clinically relevant problem. St. John's Wort (*Hypericum perforatum*) is used for depression, but activates cytochrome P450 enzymes and P-glycoprotein, dramatically lowering plasma levels of warfarin, cyclosporine and antiretroviral medicines ^[25]. To compound these problems, the inherent batch-to-batch variability in phytochemical content of herbal preparations, which depends on geographical origin, harvest season and processing processes, makes dosage standardisation exceedingly challenging.

There are still no regulatory frameworks in most parts of the world – although the WHO has issued guidelines for traditional medicine safety and good manufacturing practices, most herbal remedies have not undergone rigorous clinical trials and post-market surveillance systems for herbal adverse events are still under development in most countries^[26].

7. Innovation and Integration:

The Modern Tools Transforming the Field

Ethnopharmacology in conjunction with emerging technology is revolutionising natural product drug discovery. Artificial intelligence and machine learning algorithms are currently being used to virtually filter massive natural product databases, predicting bioactivity, toxicity and drug-likeness with surprising accuracy, drastically lowering

time and expense of early-stage discovery^[27]. Network pharmacology, a new systems approach, is mapping the intricate multi-target interactions of plant-derived chemicals with disease networks, giving mechanistic insights that explain the polypharmacological character of traditional medicines^[28].

Metabolomics, genomics and transcriptomics facilitate identification of bioactive compounds and their biosynthetic pathways. Nanotechnology improves bioavailability of natural products, while synthetic biology and gene-editing technologies enable sustainable production of complex compounds such as artemisinin^[29,30]. Tools such as molecular docking and structure-based virtual screening allow for rapid identification of natural product-target interactions at atomic resolution. In addition, integration of traditional knowledge in adaptive clinical trial designs such as the application of ethnopharmacological data to inform patient selection and dosing is the ultimate interface between ancient wisdom and evidence-based medicine^[31].

8. Ethical and Regulatory Issues:

Ethical and Regulatory Issues: Natural product-derived medicines are regulated through different frameworks worldwide, including those of the FDA, EMA and CDSCO, which oversee botanical and traditional medicinal products.

Ethical issues are still at the core of the discipline. Biopiracy, or the unauthorized appropriation of traditional knowledge and biological resources for commercial purposes without equitable sharing of benefits to the communities of origin, has been described in controversial cases related to turmeric, neem and basmati, highlighting the vulnerability of indigenous knowledge systems to exploitation^[32]. Free, prior and informed permission of traditional knowledge holders and fair benefit sharing agreements are now an ethical need in ethnobotanical research. The WHO Traditional Medicine Strategy 2019-2025 sets out to integrate traditional medicine into national health systems, develop evidence bases and promote safe, equitable access worldwide.

9. Conclusion:

Ethnopharmacology based drug development from natural compounds is one of the most prolific and historically proven approaches in pharmaceutical sciences. The review has shown that natural products have provided clinically essential therapeutics for oncology, infectious diseases, cardiovascular, neurological, inflammatory, and metabolic diseases, from artemisinin and paclitaxel to galantamine and berberine, all traceable to traditional medicinal knowledge.

But there are big obstacles. Toxicological risks include aristolochic acid nephropathy and pyrrolizidine alkaloid hepatotoxicity, and, together with difficulties in dose standardisation, herb-drug interactions and fragmented regulatory frameworks, emphasise the critical need to put all ethnopharmacological leads through rigorous preclinical and clinical evaluation.

The future of this profession is at the crossroads of old wisdom and current innovation. Artificial intelligence (AI), network pharmacology, metabolomics, nanotechnology, and synthetic biology are revolutionizing the speed, accuracy, and scalability of natural product drug discovery. However, realising this promise requires true multidisciplinary cooperation amongst ethnobotanists, pharmacologists, toxicologists, physicians, bioinformaticians and regulatory scientists, underpinned by a common commitment to ethical, evidence-based and equitable medication development.

The lasting contribution of natural products to medicine is not a legacy of the past, but rather an expanding frontier of the future, a future in which traditional knowledge, responsibly married with state-of-the-art science, holds the promise to address the most pressing unmet therapeutic needs of the 21st century.

10. References:

- 1.Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., ... & Bhutta, Z. A. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The lancet*, 396(10258), 1204-1222. [https://doi.org/10.1016/S0140-6736\(20\)30925-9](https://doi.org/10.1016/S0140-6736(20)30925-9)
- 2.Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of novel drugs over the period 1981–2019. *Journal of Natural Products*, 83(3), 770–803. <https://doi.org/10.1021/acs.jnatprod.9b01285>
- 3.Dias, D. A., Urban, S., & Roessner, U. (2012). A historical overview of natural products in drug discovery. *Metabolites*, 2(2), 303-336. <https://doi.org/10.3390/metabo2020303>

4. Kim, C.-H., Echeverria Moran, V., Hohmann, J., Echeverria, J., Yen, H.-R., Lu, A., & Heinrich, M. (2022). Editorial: Insights in ethnopharmacology: 2021. *Frontiers in Pharmacology*, 13, 997577. <https://doi.org/10.3389/fphar.2022.997577>
5. Heinrich, M., Barnes, J., Prieto-Garcia, J., Gibbons, S., & Williamson, E. M. (2017). *Fundamentals of pharmacognosy and phytotherapy e-book: Fundamentals of pharmacognosy and phytotherapy e-book*. Elsevier Health Sciences.
6. Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: advances and opportunities. *Nature reviews Drug discovery*, 20(3), 200-216. <https://doi.org/10.1038/s41573-020-00114-z>
7. Heinrich, M., Scotti, F., Andrade-Cetto, A., Berger-Gonzalez, M., Echeverría, J., Friso, F., ... & Spadafora, R. (2020). Access and benefit sharing under the Nagoya protocol—Quo Vadis? Six Latin American case studies assessing opportunities and risk. *Frontiers in pharmacology*, 11, 765. <https://doi.org/10.3389/fphar.2020.00765>
8. Leonti, M., Stafford, G. I., Dal Cero, M., Cabras, S., Castellanos, M. E., Casu, L., & Weckerle, C. S. (2017). Reverse ethnopharmacology and drug discovery. *Journal of ethnopharmacology*, 198, 417-431. <https://doi.org/10.1016/j.jep.2016.12.044>
9. Graham, J. G., Bisson, J., Harris, G. H., Wang, Z. J., Waller, D. P., & Pauli, G. F. (2024). Natural products with potential for the treatment of pain: global evidence from the NAPRALERT Database. *Journal of natural products*, 87(11), 2665-2675. <https://doi.org/10.1021/acs.jnatprod.4c00439>
10. Ojima, I. (2008). Modern natural products chemistry and drug discovery. *Journal of medicinal chemistry*, 51(9), 2587-2588. <https://doi.org/10.1021/jm701291u>
11. Carroll, A. R., Copp, B. R., Davis, R. A., Keyzers, R. A., & Prinsep, M. R. (2023). Marine natural products. *Natural product reports*, 40(2), 275-325. <https://doi.org/10.1039/D2NP00083K>
12. Das, D., & Shafi, S. (2023). Bioactivity-guided fractionation and identification of bioactive molecules: A basic method in drug discovery. In *Drugs and a Methodological Compendium: From bench to bedside* (pp. 41-78). Singapore: Springer Nature Singapore.
13. Alsaleh, A. N., Aziz, I. M., Aljowaie, R. M., Alshalan, R. M., Alkubaisi, N. A., & Aboul-Soud, M. A. (2024). In vitro evaluation, chemical profiling, and in silico ADMET prediction of the pharmacological activities of Artemisia absinthium root extract. *Pharmaceuticals*, 17(12), 1646. . <https://doi.org/10.3390/ph17121646>
14. Yan-Hua, Y. A. N. G., Jia-Wang, M. A. O., & Xiao-Li, T. A. N. (2020). Research progress on the source, production, and anti-cancer mechanisms of paclitaxel. *Chinese journal of natural medicines*, 18(12), 890-897. [https://doi.org/10.1016/S1875-5364\(20\)60032-2](https://doi.org/10.1016/S1875-5364(20)60032-2)
15. Ashley, E. A., Woodrow, C. J., & Pyae, P. A. (2018). Malaria. *The Lancet*, 391(10130), 1608-1621. [https://doi.org/10.1016/S0140-6736\(18\)30324-6](https://doi.org/10.1016/S0140-6736(18)30324-6)
16. Yang, H. Y., Chen, Y. X., Luo, S., He, Y. L., Feng, W. J., Sun, Y., ... & Gao, K. (2022). Cardiac glycosides from Digitalis lanata and their cytotoxic activities. *RSC advances*, 12(36), 23240-23251. <https://doi.org/10.1039/D2RA04464A>
17. Soni, R., Jaiswal, S., Bara, J. K., & Saksena, P. (2016). The use of Rauwolfia serpentina in hypertensive patients. *J Biotechnol Biochem*, 2(5), 28-32.
18. Tewari, D., Joshi, T., & Sah, A. N. (2021). Galanthus nivalis L.(snowdrop). In *Naturally Occurring Chemicals Against Alzheimer's Disease* (pp. 301-315). Academic Press.
19. Mahto, K., Kuwar, O. K., Maloo, A., & Kumar, A. (2025). Therapeutic potential of Boswellia serrata in arthritis management: mechanistic insights into COX-2, 5-LOX, and NFκB modulation. *Inflammopharmacology*, 33(9), 5085-5096. <https://doi.org/10.1007/s10787-025-01912-w>

20. Alnuqaydan, A. M., Almutary, A., Bhat, G. R., Mir, T. A., Wani, S. I., Rather, M. Y., ... & Rah, B. (2022). Evaluation of the cytotoxic, anti-inflammatory, and immunomodulatory effects of Withaferin A (WA) against lipopolysaccharide (LPS)-induced inflammation in immune cells derived from BALB/c mice. *Pharmaceutics*, 14(6), 1256. <https://doi.org/10.3390/pharmaceutics14061256>
21. Guo, J., Chen, H., Zhang, X., Lou, W., Zhang, P., Qiu, Y., ... & Liu, W. J. (2021). The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials. *Oxidative medicine and cellular longevity*, 2021(1), 2074610. <https://doi.org/10.1155/2021/2074610>
22. Wang, Z., Han, H., Wang, C., Zheng, Q., Chen, H., Zhang, X., & Hou, R. (2021). Hepatotoxicity of pyrrolizidine alkaloid compound intermedine: comparison with other pyrrolizidine alkaloids and its toxicological mechanism. *Toxins*, 13(12), 849. <https://doi.org/10.3390/toxins13120849>
23. Wang, Y., Su, C., Zhang, B., Niu, Y., Ren, R., Zhao, X., ... & Ma, X. (2021). Biological Activity, Hepatotoxicity, and Structure-Activity Relationship of Kavalactones and Flavokavins, the Two Main Bioactive Components in Kava (*Piper methysticum*). *Evidence-Based Complementary and Alternative Medicine*, 2021(1), 6851798. <https://doi.org/10.1155/2021/6851798>
24. Dickman, K. G., Chen, C. H., Grollman, A. P., & Pu, Y. S. (2023). Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review. *World journal of urology*, 41(4), 899-907. <https://doi.org/10.1007/s00345-022-04100-5>
25. Soleymani, S., Bahramsoltani, R., Rahimi, R., & Abdollahi, M. (2017). Clinical risks of St John's Wort (*Hypericum perforatum*) co-administration. *Expert opinion on drug metabolism & toxicology*, 13(10), 1047-1062. <https://doi.org/10.1080/17425255.2017.1378342>
26. World Health Organization. (2013). *WHO traditional medicine strategy: 2014-2023*. World Health Organization.
27. Mullowney, M. W., Duncan, K. R., Elsayed, S. S., Garg, N., van der Hooft, J. J., Martin, N. I., ... & Medema, M. H. (2023). Artificial intelligence for natural product drug discovery. *Nature Reviews Drug Discovery*, 22(11), 895-916. <https://doi.org/10.1038/s41573-023-00774-7>
28. Mukherjee, P. K., Banerjee, S., & Kar, A. (2021). Molecular combination networks in medicinal plants: understanding synergy by network pharmacology in Indian traditional medicine. *Phytochemistry reviews*, 20(4), 693-703. <https://doi.org/10.1007/s11101-020-09730-4>
29. Tabanelli, R., Brogi, S., & Calderone, V. (2021). Improving curcumin bioavailability: current strategies and future perspectives. *Pharmaceutics*, 13(10), 1715. <https://doi.org/10.3390/pharmaceutics13101715>
30. Paddon, C. J., & Keasling, J. D. (2014). Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development. *Nature reviews microbiology*, 12(5), 355-367. <https://doi.org/10.1038/nrmicro3240>
31. Wu, C., Lee, S. L., Taylor, C., Li, J., Chan, Y. M., Agarwal, R., ... & Tyner, K. (2020). Scientific and regulatory approach to botanical drug development: a US FDA perspective. *Journal of Natural Products*, 83(2), 552-562. <https://doi.org/10.1021/acs.jnatprod.9b00949>
32. Robinson, D. (2010). *Confronting biopiracy: challenges, cases and international debates*. Routledge.